Company profile: Dren Bio
1.1 - Company Overview
Company description
- Provider of protein engineering technologies for depleting cells, protein aggregates, and other disease-causing agents. Develops antibody therapeutics including DR-01, a fully human, nonfucosylated ADCC-inducing antibody for hematologic malignancies and autoimmune disorders, and a Targeted Myeloid Engager and Phagocytosis Platform with DR-0201 for B cell malignancies and DR-0202 for solid tumors.
Products and services
- Targeted Myeloid Engager and Phagocytosis Platform: A bispecific antibody-based technology engaging myeloid cells to deplete pathologic cells and deliver localized immunostimulation, reprogramming tumor-associated macrophages to reset immunosuppressive tumor microenvironments
- DR-0202: A bispecific antibody from the Targeted Myeloid Engager and Phagocytosis Platform targeting solid tumors, inducing robust cytokine release and cancer cell depletion, potentially tumor microenvironment-restricted anti-tumor activity
- DR-0201: A bispecific antibody for B cell malignancies, binding a phagocytic receptor on myeloid cells and a B-cell surface receptor to induce depletion and cytokine release
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Dren Bio
Siren Biotechnology
HQ: United States
Website
- Description: Provider of AAV immuno-gene therapies that combine AAV gene therapy and cytokine immunotherapy into a single modality for solid tumors, including brain and eye cancers. Its approach delivers engineered cytokines directly to tumors to activate immune responses and destroy cancer cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Siren Biotechnology company profile →
G1 Therapeutics
HQ: United States
Website
- Description: Provider of next-generation anticancer therapies, including trilaciclib, a transient intravenous CDK4/6 inhibitor administered before chemotherapy to protect bone marrow and enhance immune function; lerociclib, an oral CDK4/6 inhibitor for use with other therapies; and rintodestrant (G1T48), an oral SERD for estrogen receptor–positive breast cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full G1 Therapeutics company profile →
Cirrus Bio
HQ: United States
Website
- Description: Provider of solutions for common health issues that impact well-being.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cirrus Bio company profile →
Formula Pharmaceuticals
HQ: United States
Website
- Description: Provider of oncology-focused CAR immunotherapies leveraging an allogeneic source, non-viral transfection, and a differentiated immune effector cell, plus diagnostic tests and research reagents including camelid nanobodies, a canine heartworm/tick-borne disease test, a SARS-CoV-2 antigen test, phosphate assay kits, leukocyte isolation solutions, and SDS-PAGE buffers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Formula Pharmaceuticals company profile →
Marengo Therapeutics
HQ: United States
Website
- Description: Provider of T cell–modulating antibody platforms and therapeutics, including the STAR bi-functional molecule platform pairing anti-Vβ antibodies with costimulatory signals for antigen-rich 'hot' tumors; the TriSTAR T cell engager for antigen-low 'cold' tumors; TCR-targeting antibodies; an antibody technology platform using genomics and TCR sequencing; and STAR0602, in Phase I/II (START-001) for advanced antigen-rich solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Marengo Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Dren Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Dren Bio
2.2 - Growth funds investing in similar companies to Dren Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Dren Bio
4.2 - Public trading comparable groups for Dren Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →